Matches in SemOpenAlex for { <https://semopenalex.org/work/W4254118471> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W4254118471 endingPage "291" @default.
- W4254118471 startingPage "283" @default.
- W4254118471 abstract "<h3>Background.—</h3> Neutropenic patients with cancer are traditionally treated with empiric antibiotic combinations when they become febrile. The availability of broadspectrum antibiotics such as ceftazidime and imipenem has made it possible to initiate therapy with a single agent (monotherapy). The objectives of this trial were to compare ceftazidime and imipenem as single agents for the therapy of febrile episodes in neutropenic patients and to ascertain whether the addition of an aminoglycoside (amikacin) to either of these agents would provide an advantage. <h3>Methods.—</h3> A prospective clinical trial was conducted in which eligible neutropenic patients with cancer were randomized to one of four treatment arms: ceftazidime alone; imipenem alone; ceftazidime plus amikacin; and imipenem plus amikacin. Efficacy analysis was done for 750 assessable episodes. A multivariate logistic-regression analysis was also performed to examine the unique contribution of various prognostic factors. <h3>Results.—</h3> The overall response rates were 76% with imipenem plus amikacin, 72% with imipenem, 71% with ceftazidime plus amikacin, and 59% with ceftazidime alone. Single-organism gram-positive infections occurred in 101 of 750 episodes. Without a change in antibiotics, the response rates were 50% with imipenem, 40% with imipenem plus amikacin, 39% with ceftazidime plus amikacin, and 38% with ceftazidime. Most responded to vancomycin or other antibiotics, and the mortality associated with gram-positive infections was only 5%. Regardless of the antibiotic regimen, the majority of uncomplicated gramnegative infections responded to therapy and the majority of complicated gram-negative infections failed to respond. Multivariate logistic-regression analysis showed that recovery of the neutrophil count was the most favorable prognostic factor in a patient's response to infection, whereas the presence of gram-positive infection, acute leukemia, pulmonary or enteric infection, and therapy with ceftazidime were unfavorable factors. <h3>Conclusions.—</h3> Single-agent therapy with imipenem is as effective as more conventional combination antibiotic therapy for the empirical treatment of febrile episodes in neutropenic patients with cancer. (<i>Arch Intern Med</i>. 1992;152:283-291)" @default.
- W4254118471 created "2022-05-12" @default.
- W4254118471 creator A5040486044 @default.
- W4254118471 date "1992-02-01" @default.
- W4254118471 modified "2023-10-14" @default.
- W4254118471 title "A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients" @default.
- W4254118471 doi "https://doi.org/10.1001/archinte.152.2.283" @default.
- W4254118471 hasPublicationYear "1992" @default.
- W4254118471 type Work @default.
- W4254118471 citedByCount "22" @default.
- W4254118471 crossrefType "journal-article" @default.
- W4254118471 hasAuthorship W4254118471A5040486044 @default.
- W4254118471 hasConcept C126322002 @default.
- W4254118471 hasConcept C142724271 @default.
- W4254118471 hasConcept C177713679 @default.
- W4254118471 hasConcept C204787440 @default.
- W4254118471 hasConcept C2776968632 @default.
- W4254118471 hasConcept C2777427914 @default.
- W4254118471 hasConcept C2777637488 @default.
- W4254118471 hasConcept C2779181126 @default.
- W4254118471 hasConcept C2779631663 @default.
- W4254118471 hasConcept C3019249092 @default.
- W4254118471 hasConcept C501593827 @default.
- W4254118471 hasConcept C523546767 @default.
- W4254118471 hasConcept C54355233 @default.
- W4254118471 hasConcept C71924100 @default.
- W4254118471 hasConcept C86803240 @default.
- W4254118471 hasConcept C89423630 @default.
- W4254118471 hasConcept C94665300 @default.
- W4254118471 hasConceptScore W4254118471C126322002 @default.
- W4254118471 hasConceptScore W4254118471C142724271 @default.
- W4254118471 hasConceptScore W4254118471C177713679 @default.
- W4254118471 hasConceptScore W4254118471C204787440 @default.
- W4254118471 hasConceptScore W4254118471C2776968632 @default.
- W4254118471 hasConceptScore W4254118471C2777427914 @default.
- W4254118471 hasConceptScore W4254118471C2777637488 @default.
- W4254118471 hasConceptScore W4254118471C2779181126 @default.
- W4254118471 hasConceptScore W4254118471C2779631663 @default.
- W4254118471 hasConceptScore W4254118471C3019249092 @default.
- W4254118471 hasConceptScore W4254118471C501593827 @default.
- W4254118471 hasConceptScore W4254118471C523546767 @default.
- W4254118471 hasConceptScore W4254118471C54355233 @default.
- W4254118471 hasConceptScore W4254118471C71924100 @default.
- W4254118471 hasConceptScore W4254118471C86803240 @default.
- W4254118471 hasConceptScore W4254118471C89423630 @default.
- W4254118471 hasConceptScore W4254118471C94665300 @default.
- W4254118471 hasIssue "2" @default.
- W4254118471 hasLocation W42541184711 @default.
- W4254118471 hasOpenAccess W4254118471 @default.
- W4254118471 hasPrimaryLocation W42541184711 @default.
- W4254118471 hasRelatedWork W1968594847 @default.
- W4254118471 hasRelatedWork W1993698692 @default.
- W4254118471 hasRelatedWork W2005848532 @default.
- W4254118471 hasRelatedWork W2011205596 @default.
- W4254118471 hasRelatedWork W2024064315 @default.
- W4254118471 hasRelatedWork W2047617147 @default.
- W4254118471 hasRelatedWork W2090451311 @default.
- W4254118471 hasRelatedWork W2384953698 @default.
- W4254118471 hasRelatedWork W2408944882 @default.
- W4254118471 hasRelatedWork W2778662914 @default.
- W4254118471 hasVolume "152" @default.
- W4254118471 isParatext "false" @default.
- W4254118471 isRetracted "false" @default.
- W4254118471 workType "article" @default.